106
Participants
Start Date
April 28, 2021
Primary Completion Date
November 21, 2024
Study Completion Date
November 21, 2024
Semaglutide
Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
Placebo (Semaglutide)
Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
Nefrologisk Klinik P 2132, Copenhagen
Steno Diabetes Center Copenhagen, Herlev
Maxwell Centre, Durban
Precise Clinical Solutions (Pty) Ltd, Durban
Prof Rayner_Division of Nephrology, Cape Town
Istituto Scientifico San Raffaele, Milan
Azienda Ospedaliera Papa Giovanni XXIII, Bergamo
Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1, Toulouse
Advent Health-Res Inst, Orlando
Azienda Ospedaliera di Padova Clin.Med.3, Padua
Centre Hospitalier Universitaire Grenoble Alpes-Site Nord Michallon-2, Grenoble - Cédex 09
Hospital Clinico Universitario de Valencia, Valencia
Hospital Clínico Universitario de Valencia, Valencia
Centre Hospitalier Universitaire Reims-Hopital Maison Blanche, Reims
Clinical Research Consultants, LLC, Kansas City
Centre Hospitalier Universitaire de Rouen - Hopital de Bois Guillaume, Bois-Guillaume
Prolato Clinical Research Cntr, Houston
NE Clin Res of San Antonio, San Antonio
UC Anschutz Medical Campus, Aurora
Centre Hospitalier Universitaire Amiens Picardie-Site Sud, Amiens
Academic Medical Research Institute, Los Angeles
N America Res Inst - San Dimas, San Dimas
Univ of Washington Med Ctr, Seattle
Providence Medical Research Center, Spokane
UHN-Toronto General Hospital, Toronto
Azienda Ospedaliero - Universitaria Sant'Andrea, Roma
"Centrum Medyczne Diabetika", Radom
Miedzyleski Szpital Specjalistyczny, Oddzial Nefrologiczny, Warsaw
Prywatny Gabinet Janusz Gumprecht, Zabrze
Hospital Vall d'Hebron, Barcelona
Hospital de Bellvitge, L'Hospitalet de Llobregat
Lead Sponsor
Novo Nordisk A/S
INDUSTRY